Warning: Missing argument 2 for wpdb::prepare(), called in /home4/bquality/public_html/wp-content/plugins/membership/membershipincludes/classes/membershippublic.php on line 2303 and defined in /home4/bquality/public_html/wp-includes/wp-db.php on line 1291

Warning: Missing argument 2 for wpdb::prepare(), called in /home4/bquality/public_html/wp-content/plugins/membership/membershipincludes/classes/membershippublic.php on line 2303 and defined in /home4/bquality/public_html/wp-includes/wp-db.php on line 1291
Vaccine pills coming soon? | BioQuality.biz

Vaccine Pills would be real shot in the arm for vaccine industry šŸ˜‰

[click the Title above to see this entire post]

Effect of protein release rates from tablet formulations on the immune response after sublingual immunization

Borde A, Ekman A, Holmgren J, Larsson A., Eur J Pharm Sci. 2012 Aug 29. [Epub ahead of print], Pharmaceutical Technology, Chemical and Biological Engineering, Chalmers University of Technology, SE-41296 Gothenburg, Sweden.


  • This paper details research towards realization of dry vaccine formulations for sublingual administration, which would beĀ  great boon to both patients and industry “since they are easy to administer and might also have improved stability properties.”
  • This paper presents research using the model protein OvalbuminĀ in BALB/c miceĀ to determineĀ “the influence of protein release rate from mucoadhesive two-layer tablets on the elicited antibody responses after sublingual immunization.”
  • The authors studied 5 tablet types:
    • Two fast release tablets, one based on a mixture of lactose and microcrystalline cellulose (MCC) and one protein coated ethylcellulose (EC) tablet
    • Three hydrophilic matrix tablets with extended release (ER) properties based on HPMC 90 SH 100000 or CarbopolĀ® 974-P NF
  • What they measured was the in vitro release profiles of the model protein ovalbumin (OVA) from these tablets
  • This was then characterized and correlated to the in vivo potential of the tablets to induce an immune response after sublingual immunization in the BALB/c mice
  • According to the authors, “It could be concluded that a tablet with fast protein release elicits antibody titres not significantly different from titres obtained with OVA in solution, whereas low immune responses were observed with a slow release of OVA from the ER formulations.”
  • Their conclusions:
    • ER tablets seem not favorable for vaccine delivery to the sublingual mucosa
    • AĀ fast releasing tablet formulationĀ has attractive features for sublingual immunization
    • And, of course, that universal statement of all researchers everywhere: “…the use of ER formulations for sublingual vaccination has to be investigated more in detail”

To see the Abstract, and a link to obtain this paper: http://www.ncbi.nlm.nih.gov/pubmed/22959953


Take a look at all the topics we research every month for our Literature Search, our Stories, and our Current Awareness Features, and if you don’t see a topic of major interest to you, send me an email [biotext1ster@gmail.com] or text me @ 951-323-4215 and I will add it if it is appropriate to our editorial scope, which is any topic related to the quality, safety, efficacy, or availability of biopharmaceuticals and biologics.


Our Current Search Topics

Access to Medicines

ADME/DMPKĀ  [absorption, distribution, metabolism, and elimination/ drug metabolism and pharmacokinetics]–New! thanks to the reader who suggested this topic

Adverse Event Monitoring and Reporting

Analytical Methods for Characterization and Control

Anti-drug Antibodies and Unwanted Immunogenicity

At the Cutting Edge

Basic Science Relevant to Biopharma and Biologics

Bioanalytical Methods and Issues

Biological Potency, Activity, and other Biological Assays


Biosimilars, Follow-on Biologics, FOPPs, Biobetters, etc.

Carbohydrate/Glycan/Oligosaccharide/Polysaccharide Characterization and Analysis

Cellular Therapies and Regenerative Medicine

Clinical Issues

Combination Products– New! thanks to the reader who suggested this topic

Container/Closure Issues

Data Analysis, Mathematical Models and Statistics

Development Costs

Development Issues, Concerns, Strategies, etc.

Deviations, Handling and Reporting

Discovery Research

Distribution Issues

European Regulations and Regulatory Perspective

Excipient Analysis and Control

Formulation and Delivery

Gene and other Nucleic Acid Therapies and Vaccines

General Business Issues

GMP Compliance, General

Good Distribution Practice

Host Cell Proteins

Imaging–New! thanks to the reader who suggested this topic

Laboratory Issues

Manufacturing and Production Issues

Method Qualification and Validation

Microbial Analysis and Control

Molecular and Personalized Medicine

Nanomedicine and Biopharmaceuticals– New! thanks to the reader who suggest this topic

Particulate Analysis and Issues

Personalized and Molecular Medicine

Preclinical Issues

Process Monitoring, and Control, Process Analytical Technology (PAT)

Process Development

Product Development, Pre-clinical and Clinical

Protein, Glycoprotein, Peptide, and Other Bio-molecule Structure/Function

Proteins, Glycoproteins, Peptides, Antibodies and Other Biomolecules: Characterization, Analysis, and Control

Quality by Design (QbD)

Raw Material Analysis and Control

Regenerative Medicine

Regulations, General Considerations

Regulatory Agencies

Regulatory Submissions, Review, Reporting, etc.

Reference Standard Qualification and Verification

Risk Analysis and Management

Safety and Efficacy Issues

Separation Science

Stability, Aggregation, and Degradation Issues

Surveillance and Pharmacovigilance

Vaccine Development, Testing, Control, Production, Delivery, Stability


BioQuality, just what you need to know when you need to know it


Post a comment

You must be logged in to post a comment.

BioQuality.com. Copyright Ā© 2015. All rights reserved.
Turning Information into Practical Knowledge